2023年2月2日,

組織老人安德森博士加入倒帶´s董事會倒帶療法,一個公司開發first-in-class demyelination-associated疾病的治療,今天宣布了額外的資金,以日長石生命科學企業/ s加入的新投資者,參與現有投資者勃林格殷格翰集團風險基金,m .企業PMV,吉瑪Frisius昏聵,和CD3 / KU魯汶。老人安德森博士,普通合夥人日長石生命科學企業/ S,將加入倒帶療法´董事會。交易的財務細節沒有透露。所得將用於提前退療法´導致程序進入臨床開發和進一步擴大藥物候選人的公司´s管道設計恢複remyelination中樞神經係統(CNS)的函數。髓鞘形成保護層在神經元和對他們的正常運行至關重要。神經退行性疾病如多發性硬化症與損壞,髓鞘惡化,最終導致一係列症狀,如抑鬱、焦慮、易怒、甚至死亡由於分解的重要神經功能。“我們很高興歡迎日長石生命科學企業作為一種新的投資者與我們現有的投資者財團的繼續支持,”安雅Harmeier說,首席執行官在倒帶療法。“額外融資不僅加強了我們的頂級投資者基礎,但也允許我們加速我們的發展導致程序進入臨床的發展。此外,我們期待著與老人Andersson作為我們的董事會新成員。”“停止甚至恢複髓鞘脫失是一項非常具有挑戰性的任務。生成的數據回放治療到目前為止支持一個真正的小說的作用機製,並將允許該公司啟動關鍵中樞神經係統臨床試驗適應症,”老人安德森說,日長石生命科學博士學位,一般合夥人企業/ S。 “Moreover, Rewind has a strong patent estate and a team with long research and development expertise in the field of remyelination therapeutics. The combination of this extensive industry expertise and the high unmet medical need in neurogenerative disorders has convinced us to join forces with Rewind´s existing, internationally renowned investor syndicate.” Demyelinating diseases such as multiple sclerosis affect millions of patients worldwide. Rewind´s approach is based on ensuring proper functioning of myelinating oligodendrocytes and oligodendrocyte precursor cells (OPCs), both of which are drivers of the myelination process. The Company´s goal is to establish a novel therapeutic principle that is universally applicable to all demyelination diseases. This provides significant therapeutic potential for treating a broad range of demyelination-inducing conditions. ### About Rewind Therapeutics Rewind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis or nerve injuries. A common feature of these illnesses is the loss of the myelin sheath, a protective cover wrapped around the nerves. Repairing or re-installing this sheath (i.e., remyelination) is a crucial factor for halting or reversing disease progression or even curing these diseases. Rewind´s team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. Based in Leuven, Belgium, Rewind is backed by top-tier life science investors such as Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Sunstone Life Science Ventures, Gemma Frisius Fonds, and CD3/ KU Leuven. About Sunstone Life Science Ventures Sunstone Life Science Ventures is an independent European venture capital investment firm founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience. Managing total funds of €500 million, Sunstone Life Science Ventures focuses on developing and expanding early-stage Life Science companies with strong potential to achieve global success in their markets. Since the inception, Sunstone Life Science Ventures has invested in more than 50 companies in the areas of pharmaceuticals, medical technologies and diagnostics, and has completed more than 20 successful IPOs and large M&A transactions. For more information, please visit: https://sunstone.eu/ For further information please contact: Rewind Therapeutics